Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of albumin-bound sirolimus injection plus endocrine therapy in HR-positive, HER2-negative advanced breast cancer after standard treatment failure
CTR20240664Phase 2Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of nab-sirolimus in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2024; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20240664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240664.